Sweden’s Cantargia AB is moving into the spotlight after raising more funds to advance its lead asset nadunolimab through late-stage trials in non-small cell lung and pancreatic cancers.
The Stockholm-based company is raising SEK250m ($24.6m) through a rights issue, securing financing for nadunolimab which targets interleukin 1 receptor accessory protein (IL1RAP) and has been designed to counteract tumor promoting systems and stimulate the immune system to recognize and destroy tumor cells
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?